Literature DB >> 11589725

Fcgamma receptors in autoimmune diseases.

G Fossati1, R C Bucknall, S W Edwards.   

Abstract

Fcgamma-receptors (Fcgamma-R) recognise the Fc portion of IgG and thus form a link between humoral and cellular immunity. These receptors are expressed by a variety of immune cells, and they function in the binding of immune complexes or IgG-opsonised particles, such as microbial pathogens. The are three major types of Fcgamma-R, namely Fcgamma-RI (CD64), Fcgamma-RII (CD32) and Fcgamma-RIII (CD16), and these differ in their ability to bind IgG and complexes. There are many isoforms of these receptors and a number of recently identified polymorphisms in their structure. This review describes the structure and function of these Fcgamma-Rs, and highlights how gene deficiencies and polymorphisms may contribute to the pathology of human diseases.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11589725     DOI： 10.1046/j.1365-2362.2001.00881.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN： 0014-2972            Impact factor:   4.686


  13 in total

1.  Suspects in the tale of lupus-associated thrombocytopenia.

Authors:  P D Ziakas; J G Routsias; S Giannouli; A Tasidou; A G Tzioufas; M Voulgarelis
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

2.  Dimers and multimers of monoclonal IgG1 exhibit higher in vitro binding affinities to Fcgamma receptors.

Authors:  Yin Luo; Zhaojiang Lu; Stephen W Raso; Clifford Entrican; Bruce Tangarone
Journal:  MAbs       Date:  2009-09-24       Impact factor: 5.857

3.  Structural basis for Fc gammaRIIa recognition of human IgG and formation of inflammatory signaling complexes.

Authors:  Paul A Ramsland; William Farrugia; Tessa M Bradford; Caroline Tan Sardjono; Sandra Esparon; Halina M Trist; Maree S Powell; Peck Szee Tan; Angela C Cendron; Bruce D Wines; Andrew M Scott; P Mark Hogarth
Journal:  J Immunol       Date:  2011-08-19       Impact factor: 5.422

4.  Importance of avidity for an endogenous drug carrier: an antibody carrier for CpG oligonucleotides.

Authors:  Roland Cheung; Moo Cho
Journal:  Mol Pharm       Date:  2010-08-02       Impact factor: 4.939

5.  A subset of human uterine endometrial macrophages is alternatively activated.

Authors:  Amy L Jensen; Jane Collins; Emilie P Shipman; Charles R Wira; Paul M Guyre; Patricia A Pioli
Journal:  Am J Reprod Immunol       Date:  2012-08-06       Impact factor: 3.886

6.  Markedly elevated CD64 expression on neutrophils and monocytes as a biomarker for diagnosis and therapy assessment in Kawasaki disease.

Authors:  Sho Hokibara; Norimoto Kobayashi; Keiko Kobayashi; Tomonari Shigemura; Haruo Nagumo; Masahiro Takizawa; Takashi Yamazaki; Kazunaga Agematsu
Journal:  Inflamm Res       Date:  2016-03-28       Impact factor: 4.575

Review 7.  The multifactorial role of neutrophils in rheumatoid arthritis.

Authors:  Helen L Wright; Robert J Moots; Steven W Edwards
Journal:  Nat Rev Rheumatol       Date:  2014-06-10       Impact factor: 20.543

8.  Markedly elevated CD64 expressions on neutrophils and monocytes are useful for diagnosis of periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome during flares.

Authors:  Takashi Yamazaki; Sho Hokibara; Tomonari Shigemura; Norimoto Kobayashi; Kimiko Honda; Yoh Umeda; Kazunaga Agematsu
Journal:  Clin Rheumatol       Date:  2014-03-13       Impact factor: 2.980

9.  High synovial expression of the inhibitory FcgammaRIIb in rheumatoid arthritis.

Authors:  Sofia E Magnusson; Marianne Engström; Uwe Jacob; Ann-Kristin Ulfgren; Sandra Kleinau
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

Review 10.  Fcγ and Complement Receptors and Complement Proteins in Neutrophil Activation in Rheumatoid Arthritis: Contribution to Pathogenesis and Progression and Modulation by Natural Products.

Authors:  Adriana Balbina Paoliello-Paschoalato; Larissa Fávaro Marchi; Micássio Fernandes de Andrade; Luciana Mariko Kabeya; Eduardo Antônio Donadi; Yara Maria Lucisano-Valim
Journal:  Evid Based Complement Alternat Med       Date:  2015-08-05       Impact factor: 2.629
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.